Federal agencies have partnered with Ology Bioservices to expand the capacity for filling and finishing vials for COVID-19 vaccines and drugs in the United States.
The joint effort includes the Biomedical Advanced Research and Development Authority (BARDA) and the Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) on the federal side. Through their new contract awarded to Ology, the federal government will have a perpetual reservation for fill/finish capacity production on commercial filling lines for use by federal partners developing COVID-19 vaccines or therapeutic treatment.
This is a considerable rework of traditional processes, which tend to see vaccine product developers contract directly with fill-finish facilities for any fill finish services needed. However, the COVID-19 pandemic has seen supply become a consistent, major issue for the U.S. in various areas. Now, the government has decided to reserve capacity to guarantee BARDA’s sponsored product developers and manufacturers have access and capability.
A group of seven U.S. representatives recently wrote to Defense Secretary Lloyd Austin in a…
As more governments and businesses seek what artificial intelligence (AI) can offer, U.S. Reps. Troy…
A group of 14 U.S. senators recently called on the U.S. Senate Appropriations Subcommittee on…
In approving the Coast Guard Authorization Act of 2024 (H.R. 7659), the House recently authorized…
The U.S. Commerce Department recently added 37 Chinese entities to the Export Administration Regulations (EAR)…
In introducing the DHS Better Ballistic Body Armor Act (S. 4305) this month, U.S. Sens.…
This website uses cookies.